AR064616A1 - Preparacion y uso de variantes del dominio 2 de kunitz del gen de la bikunina de placenta humana - Google Patents

Preparacion y uso de variantes del dominio 2 de kunitz del gen de la bikunina de placenta humana

Info

Publication number
AR064616A1
AR064616A1 ARP070105781A ARP070105781A AR064616A1 AR 064616 A1 AR064616 A1 AR 064616A1 AR P070105781 A ARP070105781 A AR P070105781A AR P070105781 A ARP070105781 A AR P070105781A AR 064616 A1 AR064616 A1 AR 064616A1
Authority
AR
Argentina
Prior art keywords
variants
preparation
human placenta
amino acids
length
Prior art date
Application number
ARP070105781A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064616(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR064616A1 publication Critical patent/AR064616A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente solicitud se refiere a variantes del dominio 2 de Kunitz del gen de bikunina de placenta humana (hBikD2) que tiene buena expresion recombinante en sistemas de expresion adecuados, propiedades inhibidoras de enzimas, inmunologicas y anti- inflamatorias favorables y una disminucion de acumulacion en el rinon, y a su preparacion y uso. Reivindicacion 1: Inhibidores de proteasa no naturales del tipo de Kunitz que tienen una longitud de 56 - 60 aminoácidos con la forma general NH2 (extremo amino) -A-B-C-COOH (extremo carboxi), en los que A tiene al menos una longitud de 5 aminoácidos, C al menos una longitud de 10 aminoácidos.
ARP070105781A 2006-12-22 2007-12-20 Preparacion y uso de variantes del dominio 2 de kunitz del gen de la bikunina de placenta humana AR064616A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026813 2006-12-22

Publications (1)

Publication Number Publication Date
AR064616A1 true AR064616A1 (es) 2009-04-15

Family

ID=39204781

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105781A AR064616A1 (es) 2006-12-22 2007-12-20 Preparacion y uso de variantes del dominio 2 de kunitz del gen de la bikunina de placenta humana

Country Status (7)

Country Link
AR (1) AR064616A1 (es)
CL (1) CL2007003811A1 (es)
PA (1) PA8764101A1 (es)
PE (1) PE20081648A1 (es)
TW (1) TW200846356A (es)
UY (1) UY30818A1 (es)
WO (1) WO2008077478A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003649A2 (en) * 2011-06-28 2013-01-03 Inhibrx Llc Wap domain fusion polypeptides and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99585A0 (en) * 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
ATE431364T1 (de) * 1991-03-01 2009-05-15 Dyax Corp Inhibitoren der menschlichen elastase von neutrophilen
ATE275583T1 (de) * 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3469584B2 (ja) * 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
DE19629982A1 (de) * 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
IL145894A0 (en) * 1999-04-29 2002-07-25 Novo Nordisk As Use of heparin-binding antagonists in the inhibition of bradykinin release
CA2644255A1 (en) * 2006-03-08 2007-09-13 Bayer Healthcare Ag Chimeric kunitz domains and their use

Also Published As

Publication number Publication date
PA8764101A1 (es) 2009-09-17
TW200846356A (en) 2008-12-01
CL2007003811A1 (es) 2008-07-04
UY30818A1 (es) 2008-07-31
WO2008077478A1 (en) 2008-07-03
PE20081648A1 (es) 2009-01-01

Similar Documents

Publication Publication Date Title
RS54701B1 (en) PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUTION ROUTE PERMEABLE TO THE CELL
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
WO2009046220A3 (en) Lipopeptides for delivery of nucleic acids
AR051512A1 (es) Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3"
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
AR080914A1 (es) Proteinas de union al beta-amiloide
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
RS53851B1 (en) ANTIKANCERSKI PROTEIN FUNCTIONS
UY30984A1 (es) Proteinas de fusion de formula m-a para degradar péptidos beta amiloides, composiciones en base a ella, preparacion y aplicaciones.
ES2531372T3 (es) Enzimas de procesamiento fusionadas a marcadores de proteínas básicas
UY28641A1 (es) Anticuerpos
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
NZ588200A (en) Procoagulant peptides
MX2010004371A (es) Proteasa de streptomyces.
ATE458000T1 (de) Zielgerichtete fusionsproteine für die krebstherapie
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
ES2688030T3 (es) Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
RS54422B1 (en) APOPTOSIS INHIBITORS AND THEIR USES
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt

Legal Events

Date Code Title Description
FB Suspension of granting procedure